Posts
Est. 2026 · Pennsylvania
The Regional
Monopoly
57 Territories · No Competition · No Decertification · No Consequence
Each of the 57 Organ Procurement Organizations holds exclusive procurement rights in its designated service area. The best OPOs convert more than half of all potential donors. The worst convert fewer than one in four. For most of the system's history, the consequence of that gap was the same for both: the contract continued, the territory held, the monopoly was maintained. The procurement gap is not a performance failure. It is an architectural feature.
An Organ Procurement Organization is not a government agency. It is a nonprofit organization — in most cases, a hospital-affiliated or independent nonprofit — that holds a federally granted exclusive territory for organ procurement. Within its designated service area, it is the only organization authorized to approach potential donor families, coordinate with hospital death-and-dying teams, recover organs from deceased donors, and arrange transportation to transplant centers. No other organization may perform these functions within its territory. The territory is exclusive. The grant is renewable. Competition is structurally excluded by federal design.
This architecture was not accidental. The OPO territorial model was established under the National Organ Transplant Act framework because organ procurement requires sustained relationships with hospital staff, consistent protocols for brain death determination, and round-the-clock logistics infrastructure — capabilities that require organizational investment and institutional presence. A competitive procurement market, the theory ran, would destabilize these relationships and introduce inconsistency into time-critical processes.
The theory was reasonable. The consequence was a franchise system in which performance could diverge enormously between OPOs without triggering the competitive discipline that would normally force poor performers out of the market. The best OPOs in the country recover organs from more than half of all medically eligible potential donors. The worst recover from fewer than one in four. For most of the system's history, both continued operating their exclusive territories.
In any other industry, a performer that converts one in four potential customers while its competitor converts one in two would lose market share. In the OPO system, both held their territories. The exclusive grant protected the underperformer as effectively as it protected the high performer. The monopoly was indifferent to what it monopolized.
The procurement gap is the difference between the number of medically eligible potential donors — patients who die under clinical circumstances in which donation is possible — and the number of actual recovered donors. This gap is the most direct measure of OPO performance, and it varies enormously across the 57 territories.
The gap exists for multiple reasons. Some are structural: not every family that is approached consents, and consent cannot be compelled. Some are logistical: organs have narrow viability windows, and recovery requires rapid coordination across hospitals, OPO staff, and transplant centers. Some are cultural: different communities have different rates of pre-registered donors, different relationships to organ donation, different levels of trust in the healthcare system.
But a significant portion of the gap is operational — attributable to the quality of the OPO's approach to potential donor families, the proactiveness of its hospital relationship management, the adequacy of its staffing and coverage protocols, and the effectiveness of its logistics. High-performing OPOs demonstrate that the gap can be substantially closed through investment, professionalization, and sustained community engagement. Low-performing OPOs demonstrate what happens when those investments are not made — or when the operational culture has settled into the complacency that monopoly protection enables.
Independent analyses — including research published by academic transplant economists and reviewed by the Senate Finance Committee — estimated that if all OPOs performed at the level of the top-quartile performers, the number of organs recovered annually could increase by 5,000 to 8,000 or more. Against a background daily death toll of 30 patients on the waitlist, that figure is not abstract. It represents a substantial portion of the preventable deaths the system produces each year.
The 57 OPOs are not uniformly distributed across the performance range. Some territories — generally those with well-resourced organizations, strong hospital partnerships, and sustained investment in community trust-building — consistently perform near the top of the national range. Others have operated for years with documented underperformance and no competitive consequence. The grid below is a schematic illustration of the performance distribution as of the 2020–2024 CMS metrics data.
The OPO system's financial architecture contains a hidden revenue driver that is rarely examined in public discussion of transplant reform: tissue procurement. Solid organ recovery — kidneys, livers, hearts, lungs — is the public face of OPO work and the activity most directly tied to lives saved on the transplant waitlist. Tissue recovery — bones, skin, tendons, corneas, heart valves — is largely invisible but substantially more lucrative, with looser oversight and higher processing margins.
Revenue per organ: Medicare rates, regulated. Significant but limited. High operational cost. Subject to CMS performance review and potential decertification since 2020.
Revenue per donor: Significantly higher than solid organ. Processing margins on tissue can run into tens of thousands per donor. Oversight is substantially lighter — FDA regulates tissue banks but scrutiny is lower than OPTN solid organ oversight. Senate investigations have flagged financial incentives creating pressure toward tissue over solid organ focus in some OPOs.
The tissue economy creates misaligned incentives at a structural level. An OPO staff member approaching a family in an ICU is carrying both the organization's public mission — to recover organs for the waitlist — and its financial incentives — which may favor tissue recovery for its processing revenue. These incentives are not always aligned. Senate Finance Committee investigations identified OPOs where high executive compensation, lobbying spending, and entertainment expenses occurred alongside documented underperformance in solid organ recovery. The financial structure of the organization was not optimized for the public health outcome it existed to serve.
The 2020 CMS rule establishing objective OPO performance metrics was the most significant reform to the OPO system since NOTA. For the first time, OPOs would be evaluated against measurable outcomes — donation rates and transplant rates — rather than self-reported data and process compliance. OPOs falling below threshold would face recertification review. The worst performers could, in principle, be decertified and their territories opened to competition or consolidated with better performers.
The rule triggered a predictable industry response: OPO trade associations lobbied against it, argued the metrics disadvantaged large OPOs, disputed the methodology, and sought delays. Some of these arguments had technical merit. The metrics created perverse incentives in certain edge cases. But the fundamental resistance was to the principle of accountability itself — to the idea that a monopoly operating with public funds to serve a public health mission could be measured against its own stated purpose and found wanting.
As of 2025 and 2026, the reform framework is in its first operational cycle. The 2026 data evaluation period is expected to place a significant number of OPOs — estimates have ranged from a quarter to nearly half — in Tier 1 status, triggering decertification review. Whether the system will follow through on actual decertifications, what happens to territories when OPOs lose them, and whether the competitive replacement model produces better outcomes or simply different monopolists are the open questions the next phase will answer.
The OPO is the conduit layer of the organ transplant system — the infrastructure through which the source (deceased donor) is connected to the conversion (transplant). Like all conduit layers in FSA architecture, it has its own financial logic that is not identical to the logic of the system it serves. The OPO is paid per organ recovered. Its executive compensation is tied to organizational revenue. Its territory is protected from competition. Its tissue revenue exceeds its solid organ revenue in some cases. None of these features are designed to produce maximum procurement of solid organs for transplant. They are designed to produce a viable nonprofit organization that also, incidentally, recovers organs. The insulation is the nonprofit designation — which implies mission alignment that the financial structure does not always provide.
Next · Post IV · The Discard — 20–29% kidney discard rates. Risk aversion as rational transplant center behavior. The algorithm's role in waste. The organs that could have saved lives and didn't.
